Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?

Jul 25 2011

• By Shirley Haley

Related Content

Effient Approval Shows Mark Of FDA Controls

Jul 15 2009

AstraZeneca Gives FDA More Data On Brilinta Interaction With High-Dose Aspirin

Jan 21 2011

Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts

Sep 02 2009

FDA Updates Plavix Label, Leaves Effient With Clear Advantage

Nov 23 2009

AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?

Sep 07 2009

Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta

Aug 09 2010

Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results

Jul 28 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window